Clinical Trial

Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke

Study acronym: HALTI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 24, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-07-14; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Recruiting 2021-02-24
Trial Details
NCT Number NCT04475510
Lead Sponsor Josep Rodes-Cabau
Conditions Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
Enrollment 100 participants
Start Date 2020-07-08
Primary Completion 2026-06-01 (estimated)
Study Completion 2032-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-24